EVOLVE II QCA: A Prospective, Multicenter Trial to Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)

Inclusion Criteria: * Subject must be at least 18 years of age * Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed * For subjects less than 20 years of age enrolled at a Japanese site, the subject and the subject's legal representative must provide written informed consent before any study-specific tests or procedures are performed * Subject is eligible for percutaneous coronary intervention (PCI) * Subject has symptomatic coronary artery disease with objective evidence of ischemia or silent ischemia * Subject is an acceptable candidate for coronary artery bypass grafting (CABG) * Subject is willing to comply with all protocol-required follow-up evaluation Angiographic Inclusion Criteria (visual estimate) * Target lesion(s) must be located in a native coronary artery with a visually estimated reference vessel diameter (RVD) ≥2.25 mm and ≤4.0 mm * Target lesion(s) length must be ≤34 mm (by visual estimate) * Target lesion(s) must have visually estimated stenosis ≥50% and \<100% with thrombolysis in Myocardial Infarction (TIMI) flow \>1 and one of the following (stenosis ≥70%, abnormal fractional flow reserve (FFR), abnormal stress or imaging stress test, or elevated biomarkers prior to the procedure) * Coronary anatomy is likely to allow delivery of a study device to the target lesions(s) * The first lesion treated must be successfully pre-dilated/pretreated Exclusion Criteria: * Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute ST elevation MI (STEMI) * Subject has cardiogenic shock, hemodynamic instability requiring inotropic or mechanical circulatory support, intractable ventricular arrhythmias, or ongoing intractable angina * Subject has received an organ transplant or is on a waiting list for an organ transplant * Subject is receiving or scheduled to receive chemotherapy within 30 days before or after the index procedure * Planned PCI (including staged procedures) or CABG after the index procedure * Subject previously treated at any time with intravascular brachytherapy * Subject has a known allergy to contrast (that cannot be adequately premedicated) and/or the trial stent system or protocol-required concomitant medications (e.g., platinum, platinum-chromium alloy, stainless steel, everolimus or structurally related compounds, polymer or individual components, all P2Y12 inhibitors (clopidogrel, ticlopidine, prasugrel, or ticagrelor), or aspirin) * Subject has one of the following (as assessed prior to the index procedure): * Other serious medical illness (e.g., cancer, congestive heart failure) with estimated life expectancy of less than 24 months * Current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.) * Planned procedure that may cause non-compliance with the protocol or confound data interpretation * Subject is receiving chronic (≥72 hours) anticoagulation therapy (i.e., heparin, coumadin) for indications other than acute coronary syndrome * Subject has a platelet count \<100,000 cells/mm3 or \>700,000 cells/mm3 * Subject has a white blood cell (WBC) count \< 3,000 cells/mm3 * Subject has documented or suspected liver disease, including laboratory evidence of hepatitis * Subject is on dialysis or has baseline serum creatinine level \>2.0 mg/dL (177µmol/L) * Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions * Subject has had a history of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months * Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding * Subject has severe symptomatic heart failure (i.e., New York Heart Association (NYHA) class IV) * Subject is participating in another investigational drug or device clinical trial that has not reached its primary endpoint * Subject intends to participate in another investigational drug or device clinical trial within 12 months after the index procedure * Subject with known intention to procreate within 12 months after the index procedure (women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure) * Subject is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential) Angiographic Exclusion Criteria (visual estimate) Planned treatment of more than 3 lesions * Planned treatment of lesions in more than 2 major epicardial vessels * Planned treatment of a single lesion with more than 1 stent * Subject has 2 target lesions in the same vessel that are separated by less than 15 mm (by visual estimate) * Target lesion(s) is located in the left main * Target lesion(s) is located within 3 mm of the origin of the left anterior descending (LAD) coronary artery or left circumflex (LCx) coronary artery by visual estimate. * Target lesion(s) is located within a saphenous vein graft or an arterial graft * Target lesion(s) will be accessed via a saphenous vein graft or arterial graft * Target lesion(s) with a TIMI flow 0 (total occlusion) or TIMI flow 1 prior to guide wire crossing * Target lesion(s) treated during the index procedure that involves a complex bifurcation (e.g., bifurcation lesion requiring treatment with more than 1 stent) * Target lesion(s) is restenotic from a previous stent implantation or study stent would overlap with a previous stent * Subject has unprotected left main coronary artery disease (\>50% diameter stenosis) * Subject has been treated with any type of PCI (i.e., balloon angioplasty, stent, cutting balloon atherectomy) within 24 hours prior to the index procedure * Thrombus, or possible thrombus, present in the target vessel (by visual estimate)